ABSTRACT In this study, a new series of polyaryl imidazole derivatives (4a‐4l) were designed, synthesized for the first time and evaluated in vitro and in vivo on key molecular targets. The structure of all compounds were characterized by FT‐IR, 1 H / 13 C NMR and elemental analysis. The compounds were tested for their antimicrobial activity as well as their inhibitory activity against cholinesterases (AChE and BChE, which are Alzheimer's‐associated enzymes). Among twelve derivatives, 4‐(4,5‐diphenyl‐2‐(p‐tolyl)‐1H‐imidazol‐1‐yl)‐N,N‐dimethylaniline (4k) displayed the strongest dual inhibitory activity (IC 50 = 6.79 µM for AChE; 7.67 µM for BChE). They demonstrated moderate antifungal activity against Candida albicans (compounds 4a, 4c, 4 h, and 4j, 15‐17 mm; MIC 0.004‐0.5 µg/mL; MFC 0.002‐0.25 µg/mL). Protein‐ligand interactions were observed through in silico docking studies and their drug likeness properties were studied through ADMET analysis.
Mercan et al. (Sun,) studied this question.